Neuron23 Announces Usage of Roche’s Digital Biomarker and Device in Parkinson’s Disease Clinical Trial
Digital biomarker to enhance precision, reduce patient burden and boost efficiency of global Phase 2 trial of NEU-411 in early Parkinson’s disease
Neuron23 Unveils Groundbreaking Phase 2 Trial in Early Parkinson’s Disease
NEU-411, a brain-penetrant, potent and selective kinase inhibitor, has potential to slow disease progression in up to 30% of people with LRRK2-driven Parkinson’s disease
Capsida Biotherapeutics to Present New Preclinical Data for Potential Best-in-Class Friedreich’s Ataxia Next-Generation Gene Therapy
NHP data demonstrate potential for CAP-004 to treat CNS, cardiac, and sensory manifestations of Friedreich’s ataxia
FDA Grants Orphan Drug Designation to Capsida Biotherapeutics for Potential Treatment of STXBP1 Developmental and Epileptic Encephalopathy
Capsida Biotherapeutics (“Capsida”) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Capsida for CAP-002.
Latigo Biotherapeutics Doses First Participant in Phase 1 Clinical Trial of LTG-305 for Non-Opioid Treatment of Pain
Latigo Biotherapeutics, Inc. (“Latigo”) today announced that the first participant has been dosed in its Phase 1 clinical trial of LTG-305, a potential best-in-class non-opioid therapeutic candidate for the treatment of chronic pain.
ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease
ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the formation of a scientific and patient advisory board comprised of leading experts and advocates in thyroid eye disease (TED)
New Data Demonstrate Substantial Therapeutic Potential of Capsida’s IV Gene Therapy for Parkinson’s Disease Associated with GBA Mutations
CAP-003 achieved best-in-class GCase increases in NHPs exceeding levels needed for normalizing activity in patients
Kyverna Therapeutics Announces Leadership Update
Warner Biddle Appointed as Chief Executive Officer and to Board of Directors, Bringing Over 30 Years of Commercial, Product Planning and Franchise Leadership Experience, Including Successful Launches for CAR T Pioneer in Hematology
Astellas Highlights Commitment to Gene Therapy and Kate Therapeutics Collaboration
In a recent article in Endpoints, Astellas highlights its work in gene therapy and commitment to rare diseases, including its collaboration with Kate Therapeutics.
Latigo Biotherapeutics Appoints Tim Lugo as Chief Financial Officer and Adds Beth Seidenberg and Jim Tananbaum to Board of Directors
Latigo Biotherapeutics Inc. (“Latigo”), a clinical-stage biotechnology company developing best-in-class non-opioid pain medicines that target pain at its source, today announced the appointment of Tim Lugo as chief financial officer (CFO). In addition, Latigo has appointed Beth Seidenberg, M.D., and Jim Tananbaum, M.D., to its board of directors. These appointments bring deep expertise and leadership as Latigo scales to rapidly advance its lead clinical programs.